Accession Number:

AD1088491

Title:

Novel Target and Lead Compound to Reverse TBI-Induced Alzheimer's-Related Dementia

Descriptive Note:

Technical Report,30 Sep 2018,29 Sep 2019

Corporate Author:

University of Colorado Denver United States

Personal Author(s):

Report Date:

2019-10-01

Pagination or Media Count:

8.0

Abstract:

It is estimated that 1.4 million Americans each year suffer a traumatic brain injury TBI, defined as a blunt or penetrating injury to the head that alters brain function. Importantly, TBI is also a major health issue in the U.S. military, with estimates of TBI prevalence as high as 23 of returning service members including both moderatesevere and mild concussive TBI. Mild concussive and moderatesevere TBI have both been linked to immediate and delayed development of long-term disabilities predominantly reduced working memory, difficulty learning new information, execute function and reasoning. Interestingly, a similar array of cognitive deficits are observed in patients with Alzheimers disease AD and AD related dementias ADRD. Relevant to the current Program Announcement, there is an emerging consensus that traumatic brain injury TBI is associated with increased risk of future AD and ADRD and military personnel are increasingly living with TBI and associated risk of cognitive decline. Thus, it is critical to improve our understanding of the etiology of TBI-induced dementia and cognitive dysfunction with the goal of identifying new therapeutic targets to improve quality of life for the thousands to millions of military and civilian individuals living with TBI.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE